BMY:NYE-Bristol-Myers Squibb Company (USD)

COMMON STOCK | Drug Manufacturers-General | NYE

Last Closing Price

USD 74.86

Change

-0.10 (-0.13)%

Market Cap

USD 157.58B

Volume

8.32M

Avg Analyst Target

USD 74.50 (-0.48%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BMY Stock Forecast & Price:
Based on the Bristol-Myers Squibb Company stock forecasts from 11 analysts, the average analyst target price for Bristol-Myers Squibb Company is USD 74.50 over the next 12 months. Bristol-Myers Squibb Company’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Bristol-Myers Squibb Company is Bearish, which is based on 5 positive signals and 12 negative signals. At the last closing, Bristol-Myers Squibb Company’s stock price was USD 74.86. Bristol-Myers Squibb Company’s stock price has changed by +2.56% over the past week, -0.69% over the past month and +11.10% over the last year.

About Bristol-Myers Squibb Company (BMY:NYE)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revli ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

+0.49 (+0.29%)

USD447.49B 24.77 16.25
LLY Eli Lilly and Company

+1.59 (+0.52%)

USD286.31B 48.06 35.87
PFE Pfizer Inc

+0.17 (+0.34%)

USD279.25B 9.61 7.79
ABBV AbbVie Inc

+0.69 (+0.49%)

USD247.07B 19.77 19.00
MRK Merck & Company Inc

-0.33 (-0.37%)

USD226.78B 13.67 12.06
NVS Novartis AG ADR

+0.28 (+0.32%)

USD188.01B 8.40 6.24
GSK GlaxoSmithKline PLC ADR

-1.73 (-4.32%)

USD81.94B 14.60 10.24
AGN Allergan plc

N/A

USD63.66B 22.00 28.44

ETFs Containing BMY

Symbol Name Weight Mer Price(Change) Market Cap
UC82:LSE UBS Barclays US Liquid Co.. 1.35 % 0.18 %

+5.75 (+0.45%)

USD0.03B
UC86:LSE UBS Barclays US Liquid Co.. 1.35 % 0.25 %

+0.06 (+0.46%)

USD0.28B
UC98:LSE UBS(Lux)Fund Solutions .. 0.74 % 0.25 %

-9.25 (-0.72%)

USD0.21B
UC97:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.25 %

+0.09 (+0.58%)

USD0.21B
BSUS:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.25 %

+5.35 (+0.56%)

USD0.09B
UET0:XETRA UBS(Lux)Fund Solutions .. 0.65 % 0.20 %

+0.14 (+0.94%)

USD0.23B
UET0:F UBS (Lux) Fund Solutions .. 0.65 % 0.20 %

+0.11 (+0.76%)

N/A
QUIG:CA Mackenzie US Investment G.. 0.62 % 0.17 %

N/A

USD0.46B
UC76:LSE UBS Barclays US Liquid Co.. 0.53 % 0.25 %

+0.09 (+0.59%)

USD0.11B
UC85:LSE UBS Barclays US Liquid Co.. 0.53 % 0.18 %

+8.75 (+0.60%)

USD0.09B
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

N/A
XMAF:LSE Xtrackers MSCI Africa Top.. 0.00 % 0.65 %

+0.19 (+2.79%)

USD0.03B
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.65 %

+2.25 (+0.83%)

N/A
XGLF:LSE db x-trackers MSCI GCC Se.. 0.00 % 0.65 %

+0.55 (+2.02%)

USD0.04B
XMAD:LSE Xtrackers - MSCI EM Asia .. 0.00 % 0.35 %

+0.28 (+0.53%)

USD0.72B
XSFR:LSE Xtrackers S&P Select Fron.. 0.00 % 0.95 %

+9.25 (+0.77%)

USD0.09B
XMAS:LSE Xtrackers MSCI EM Asia ES.. 0.00 % 0.35 %

-36.50 (-0.84%)

USD0.28B
XSFD:LSE Xtrackers S&P Select Fron.. 0.00 % 0.95 %

+0.31 (+2.10%)

USD0.08B
OUFH:XETRA Ossiam US ESG Low Carbon .. 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

+1.10 (+0.42%)

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.49 %

-0.05 (-0.45%)

USD0.04B
VMUS:XETRA VanEck Vectors ETFs N.V. .. 0.00 % 0.00 %

N/A

USD9.21M
XGLF:XETRA db x-trackers MSCI GCC Se.. 0.00 % 0.65 %

+0.22 (+0.82%)

USD0.04B
XMKA:XETRA Xtrackers MSCI Africa Top.. 0.00 % 0.65 %

+0.08 (+1.20%)

USD0.03B
ZGEN:CA BMO MSCI Genomic Innovati.. 0.00 % 0.40 %

+0.34 (+1.55%)

N/A
JSTC Tidal ETF Trust - Adasina.. 0.00 % 0.89 %

+0.40 (+2.63%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.49 %

-0.03 (-0.28%)

USD0.03B
CVY Invesco Zacks Multi-Asset.. 0.00 % 1.00 %

+0.57 (+2.54%)

USD0.11B
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.25 %

-10.00 (-0.79%)

USD0.11B
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+1.08 (+2.49%)

USD0.24B
IBDP iShares iBonds Dec 2024 T.. 0.00 % 0.10 %

+0.09 (+0.36%)

USD1.67B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+2.13 (+1.13%)

USD0.44B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

+0.68 (+1.44%)

USD0.04B
PILL Direxion Daily Pharmaceut.. 0.00 % 0.97 %

+0.80 (+6.90%)

USD0.01B
QLTA iShares Aaa - A Rated Cor.. 0.00 % 0.15 %

+0.36 (+0.73%)

USD0.88B
RFDA RiverFront Dynamic US Div.. 0.00 % 0.52 %

+0.73 (+1.59%)

USD0.10B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.34 (-2.63%)

USD2.98M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.34 (-2.63%)

USD2.98M
VVL:CA Vanguard Global Value Fac.. 0.00 % 0.38 %

+0.66 (+1.73%)

USD0.29B
ZLU:CA BMO Low Volatility US Equ.. 0.00 % 0.30 %

-0.12 (-0.26%)

USD1.26B
GBF iShares Government/Credit.. 0.00 % 0.20 %

+0.14 (+0.13%)

USD0.16B
HHL:CA Healthcare Leaders Income.. 0.00 % 0.99 %

+0.09 (+1.10%)

USD0.33B
HUL:CA Harvest US Equity Plus In.. 0.00 % 2.58 %

N/A

USD7.80M
PRP:CA Purpose Conservative Inco.. 0.00 % 0.69 %

N/A

USD1.96M
BVAL Brand Value ETF 0.00 % 0.65 %

N/A

USD9.33M
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.15 %

+0.06 (+0.24%)

USD0.25B
ULVM VictoryShares USAA MSCI U.. 0.00 % 0.20 %

+1.18 (+1.85%)

USD0.27B
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

+0.04 (+0.47%)

N/A
HUL-U:CA Harvest US Equity Plus In.. 0.00 % 0.00 %

N/A

N/A
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.35 %

+0.01 (+0.06%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.06% 100% A+ 93% A
Dividend Return 2.60% 75% C 68% D+
Total Return 22.66% 100% A+ 93% A
Trailing 12 Months  
Capital Gain 11.95% 63% D 88% B+
Dividend Return 3.16% 38% F 55% F
Total Return 15.10% 63% D 88% B+
Trailing 5 Years  
Capital Gain 31.96% 50% F 64% D
Dividend Return 15.88% 38% F 62% D-
Total Return 47.84% 50% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 4.39% 38% F 53% F
Dividend Return 3.10% 50% F 66% D
Total Return 7.50% 25% F 54% F
Risk Return Profile  
Volatility (Standard Deviation) 17.32% 50% F 62% D-
Risk Adjusted Return 43.27% 13% F 63% D
Market Capitalization 157.58B 25% F 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.52 38% F 27% F
Price/Book Ratio 4.78 63% D 16% F
Price / Cash Flow Ratio 9.72 88% B+ 41% F
EV/EBITDA 9.56 75% C 46% F
Management Effectiveness  
Return on Equity 19.09% 13% F 73% C
Return on Invested Capital 7.45% 13% F 57% F
Return on Assets 6.26% 13% F 77% C+
Debt to Equity Ratio 110.00% 50% F 32% F
Technical Ratios  
Dividend Yield 3.00% 38% F 47% F
Short Ratio 2.25 38% F 50% F
Short Percent 1.28% 13% F 75% C
Beta 0.39 63% D 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector